Reid M Huber
CIK 1607052 · EVP, Chief Scientific Officer · last filed 2026-06-10
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
INCY price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
201 BROOKLINE AVENUE, SUITE 1401
BOSTON, MA 02215
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RAPP | Director | 20,400 | $25.33 | $516.7K | $499.4K | 3 | 2026-06-10 |
| CARGO Therapeutics, Inc. (CRGX) Delisted | Director | — | $4.47 | — | $0 | 4 | 2025-08-19 |
| TNGX | Director | 5,000 | $22.20 | $111.0K | $0 | 2 | 2023-06-08 |
| BELLICUM PHARMACEUTICALS, INC (BLCM) Delisted | Director | 146,951 | $0.07 | $11.0K | $0 | 13 | 2023-01-20 |
| INCY | EVP, Chief Scientific Officer | 34,571 | $113.31 | $3.92M | -$9.61M | 25 | 2018-07-18 |
Recent Filings · Page 3 of 5
47 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-06-18 | BELLICUM PHARMACEUTICALS, INC (BLCM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-02-22 | INCY | Mixed | −3,022 | -$259.0K | EDGAR |
| 2018-01-25 | INCY | Grant (A) | — | $0 | EDGAR |
| 2017-12-05 | INCY | Sell (S) | −696 | -$68.2K | EDGAR |
| 2017-09-15 | INCY | Tax (F) | −692 | -$85.2K | EDGAR |
| 2017-07-07 | INCY | Grant (A) | +3,517 | $0 | EDGAR |
| 2017-06-15 | BELLICUM PHARMACEUTICALS, INC (BLCM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-05-09 | INCY | Mixed | −16,309 | -$1.99M | EDGAR |
| 2017-03-01 | INCY | Sell (S) | −2,008 | -$264.8K | EDGAR |
| 2017-02-28 | INCY | Mixed | +2,008 | -$132.9K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.